ClinicalTrials.gg
RecruitingNCT04613778Updated Sep 13, 2023

Correction of Breech Presentation With Laser Acupuncture

An interventional study of Laser acupuncture in Breech Presentation, sponsored by Chang Gung Memorial Hospital. Recruiting at 1 site in Taiwan. Open to female participants aged 20 Years to 36 Years. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Chang Gung Memorial Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Jun 2020, registered Oct 2020).
  • Started Jun 2020; still recruiting 6 years 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 36 Years
Sex
Female
01

Study summary

Acupuncture-type interventions (such as moxibustion and acupuncture) at Bladder 67 (BL67, Zhiyin point) have been proposed to have positive effects on breech presentation. However, the role of laser acupuncture for Breech presentation remains unknown. The aim of this study is to evaluate the effectiveness and safety of laser acupuncture in correcting breech presentation.

02

Conditions studied

  • Breech Presentation

Browse trials for

03

In context

Breech Presentation

41 studies on the registry are indexed under Breech Presentation; 10 are open to participants now.

This study's planned enrollment of 30 is below the median of 119 across 31 interventional studies indexed under Breech Presentation.

Browse Breech Presentation studies →

Lead sponsor

Chang Gung Memorial Hospital is the lead sponsor of 1,096 studies on the registry; 239 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 36 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • breech presentation or non-cephalic presentation
  • gestation age 28\~34 weeks
  • singleton

Exclusion criteria

Exclusion Criteria:

  • uterus anomaly
  • uterus tumors
  • risk of preterm labor
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Laser acupuncture

    Laser acupuncture with knee-chest position

    Procedure: Laser acupuncture

  • No intervention
    No intervention

    usual care with knee-chest position

Interventions

  • ProcedureLaser acupuncture

    Laser acupuncture is a low-level laser technique with no invasive procedure

06

What researchers measure

Primary outcomes

  1. Cephalic presentation at gestation age (GA) of 36 weeks

    numbers of cephalic presentation confirmed by ultrasound

    Time frame: at gestation age (GA) 36 weeks

Secondary outcomes

  1. Cephalic presentation at labor

    confirmed by ultrasound

    Time frame: numbers of cephalic presentation at labor (an average of GA 38 weeks)

Other outcomes

  1. adverse events

    Time frame: through study completion, an average of 6 weeks

  2. preterm labor

    Time frame: through study completion, an average of 6 weeks

  3. methods of delivery

    C/S or vaginal delivery

    Time frame: at labor, an average of GA 38 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2020 (actual). Primary completion is estimated for Oct 2024, 52 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2020
First posted
Nov 3, 2020
StartActual
Jun 1, 2020
Primary completionEst.
Oct 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04613778
Responsible party
Sponsor
First posted
Nov 3, 2020
Start date
Jun 1, 2020
Primary completion
Oct 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Sep 13, 2023

Study contacts

YEH YUAN-CHIEH
Contact
b9005030@cgmh.org.tw
24313131 ext. 6321

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion